Gossamer Bio's lead asset, seralutinib, shows promise in Phase 2 for PAH, but Phase 3 efficacy and competition from established drugs remain concerns. The company is well capitalized with $295 million ...
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...
SAN DIEGO, November 05, 2025--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for ...
Gossamer Bio Inc. (NASDAQ:GOSS) is one of the best biotech stocks to invest in now. On June 16, Gossamer Bio announced the completion of enrollment for its global registrational Phase 3 PROSERA Study.
SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...
Gossamer Bio and Chiesi Farmaceutici (the Chiesi Group) have announced a worldwide partnership and licence agreement to develop and market seralutinib for pulmonary hypertension. The partnership will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results